Blue­bird bio or­ches­trates a se­ries of deals and a buy­out to guar­an­tee gene ther­a­py man­u­fac­tur­ing

A day af­ter The New York Times spot­light­ed the man­u­fac­tur­ing and sup­ply prob­lems be­set­ting a boom­ing gene ther­a­py field, with key play­ers scram­bling to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.